JP7034078B2 - セラストロールの類似体 - Google Patents

セラストロールの類似体 Download PDF

Info

Publication number
JP7034078B2
JP7034078B2 JP2018541085A JP2018541085A JP7034078B2 JP 7034078 B2 JP7034078 B2 JP 7034078B2 JP 2018541085 A JP2018541085 A JP 2018541085A JP 2018541085 A JP2018541085 A JP 2018541085A JP 7034078 B2 JP7034078 B2 JP 7034078B2
Authority
JP
Japan
Prior art keywords
mmol
administration
solution
reaction
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018541085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531289A (ja
JP2018531289A5 (https=
JP2018531289A6 (ja
Inventor
ラルフ マージシェック
ヤンビン ディン
カイシェン シェン
Original Assignee
イーアールエックス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーアールエックス ファーマシューティカルズ インコーポレイテッド filed Critical イーアールエックス ファーマシューティカルズ インコーポレイテッド
Publication of JP2018531289A publication Critical patent/JP2018531289A/ja
Publication of JP2018531289A6 publication Critical patent/JP2018531289A6/ja
Publication of JP2018531289A5 publication Critical patent/JP2018531289A5/ja
Priority to JP2021179997A priority Critical patent/JP7339992B2/ja
Application granted granted Critical
Publication of JP7034078B2 publication Critical patent/JP7034078B2/ja
Priority to JP2023136867A priority patent/JP2023164877A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Optical Filters (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018541085A 2015-10-23 2016-10-21 セラストロールの類似体 Active JP7034078B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021179997A JP7339992B2 (ja) 2015-10-23 2021-11-04 セラストロールの類似体
JP2023136867A JP2023164877A (ja) 2015-10-23 2023-08-25 セラストロールの類似体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245356P 2015-10-23 2015-10-23
US62/245,356 2015-10-23
PCT/US2016/058313 WO2017070615A1 (en) 2015-10-23 2016-10-21 Analogs of celastrol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021179997A Division JP7339992B2 (ja) 2015-10-23 2021-11-04 セラストロールの類似体

Publications (4)

Publication Number Publication Date
JP2018531289A JP2018531289A (ja) 2018-10-25
JP2018531289A6 JP2018531289A6 (ja) 2018-12-13
JP2018531289A5 JP2018531289A5 (https=) 2019-12-05
JP7034078B2 true JP7034078B2 (ja) 2022-03-11

Family

ID=58558149

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018541085A Active JP7034078B2 (ja) 2015-10-23 2016-10-21 セラストロールの類似体
JP2021179997A Active JP7339992B2 (ja) 2015-10-23 2021-11-04 セラストロールの類似体
JP2023136867A Withdrawn JP2023164877A (ja) 2015-10-23 2023-08-25 セラストロールの類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021179997A Active JP7339992B2 (ja) 2015-10-23 2021-11-04 セラストロールの類似体
JP2023136867A Withdrawn JP2023164877A (ja) 2015-10-23 2023-08-25 セラストロールの類似体

Country Status (8)

Country Link
US (3) US10662218B2 (https=)
EP (1) EP3364956A4 (https=)
JP (3) JP7034078B2 (https=)
CN (2) CN119241632A (https=)
AU (3) AU2016342375B2 (https=)
BR (1) BR112018008103A2 (https=)
MA (1) MA45430A (https=)
WO (1) WO2017070615A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022017473A (ja) * 2015-10-23 2022-01-25 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4610656A3 (en) 2016-04-15 2025-11-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
AU2017285486B2 (en) * 2016-06-15 2023-04-27 Targa Biomedical Reagents, compositions and methods for improving viability and function of cells, tissues and organs
JP2019523245A (ja) * 2016-07-04 2019-08-22 厦▲門▼大学 オーファン核内受容体Ｎｕｒ７７のリガンド及びその使用
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112094313B (zh) * 2019-06-17 2023-07-04 中国科学院上海药物研究所 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途
CN112110977B (zh) * 2019-06-21 2022-02-25 中国科学院上海药物研究所 一类雷公藤红素衍生物、其制备方法及用途
AU2021207672A1 (en) 2020-01-15 2022-07-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
WO2022072094A2 (en) * 2020-08-28 2022-04-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof
CN115677812B (zh) * 2022-01-18 2023-12-15 聊城大学 一类雷公藤红素衍生物及其制备方法与应用
WO2023249354A1 (ko) * 2022-06-21 2023-12-28 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 근육 감소로 인한 질환 예방 또는 치료용 약학 조성물
WO2024015416A1 (en) * 2022-07-15 2024-01-18 Celloram Inc. Celastrol derivatives
EP4618998A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Celastrol salts, crystalline forms, and uses thereof
EP4618964A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Compositions and methods for treatment of prader-willi syndrome
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20110166216A1 (en) 2007-08-17 2011-07-07 Burnham Institute For Medical Research Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma
JP2013536203A (ja) 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
WO2014052583A1 (en) 2012-09-27 2014-04-03 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
JP2015520170A (ja) 2012-05-25 2015-07-16 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
WO2015148802A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
FR2875913A1 (fr) 2004-09-29 2006-03-31 Sea On Line Sa Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2008063513A2 (en) * 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
AU2013266252B2 (en) 2012-05-25 2017-07-06 Spm Oil & Gas Inc. Evaluating systems associated with wellheads
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
EP3563343A4 (en) 2017-01-02 2020-08-19 Gauss Surgical, Inc. SURGICAL ITEM FOLLOW-UP WITH DUAL ELEMENT IMAGING PREDICTION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
US20110166216A1 (en) 2007-08-17 2011-07-07 Burnham Institute For Medical Research Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma
JP2013536203A (ja) 2010-08-23 2013-09-19 スーチョウ・ニューファーマ・カンパニー・リミテッド 特定の化学成分、組成物および方法
JP2015520170A (ja) 2012-05-25 2015-07-16 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
WO2014052583A1 (en) 2012-09-27 2014-04-03 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015148802A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS Chemical Biology，2012年03月01日，Vol.7，pp.928-937，DOI:10.1021/cb200539u
TANG,K. et al，Design, synthesis and biological evaluation of C(6)-modified celastrol derivatives as potential antitumor agents，Molecules，2014年07月14日，Vol.19, No.7，p.10177-10188
日本臨床６８巻 増刊号２（通巻第９７２号） 肥満症（第２版）－基礎・臨床研究の進歩－，2010年02月28日，pp.486-490

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022017473A (ja) * 2015-10-23 2022-01-25 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
JP7339992B2 (ja) 2015-10-23 2023-09-06 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
JP2023164877A (ja) * 2015-10-23 2023-11-14 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Also Published As

Publication number Publication date
JP2022017473A (ja) 2022-01-25
EP3364956A4 (en) 2019-05-01
JP2023164877A (ja) 2023-11-14
US11753436B2 (en) 2023-09-12
AU2024201504A1 (en) 2024-03-28
AU2022204238A1 (en) 2022-07-07
JP2018531289A (ja) 2018-10-25
CN108601751A (zh) 2018-09-28
AU2016342375A1 (en) 2018-05-17
RU2018118633A (ru) 2019-11-25
US20240190911A1 (en) 2024-06-13
CN119241632A (zh) 2025-01-03
US20180362575A1 (en) 2018-12-20
CA3002924A1 (en) 2017-04-27
US10662218B2 (en) 2020-05-26
MA45430A (fr) 2019-05-01
AU2016342375B2 (en) 2022-03-17
US20210061851A1 (en) 2021-03-04
WO2017070615A1 (en) 2017-04-27
BR112018008103A2 (pt) 2018-11-06
EP3364956A1 (en) 2018-08-29
AU2022204238B2 (en) 2023-12-14
JP7339992B2 (ja) 2023-09-06
RU2018118633A3 (https=) 2020-02-17

Similar Documents

Publication Publication Date Title
JP7339992B2 (ja) セラストロールの類似体
JP2018531289A6 (ja) セラストロールの類似体
JP5798154B2 (ja) ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
JP6516341B2 (ja) Ｎａｓｈ関連肝臓癌を治療するためのｅｐ４受容体拮抗薬の使用
AU2014340182A1 (en) Cromolyn derivatives and related methods of imaging and treatment
JP2009533457A (ja) Ｃ−ニトロソから誘導されるニトロキシル供与体
WO2007105650A1 (ja) ４－ヒドロキシイソロイシン誘導体および同誘導体の製造方法
JP2026048875A (ja) インスリン耐性における使用方法のための治療化合物
WO2022194221A1 (zh) 呋喃稠环取代的戊二酰亚胺类化合物
US20230390296A1 (en) Novel treatment and prevention of sarcopenia-related diseases
JP2013542183A (ja) セスタテルペン化合物およびこれらの物質の用途
WO2022230920A1 (ja) 血中カルニチン増加剤
US20250092086A1 (en) Celastrol salts, crystalline forms, and uses thereof
JP2024515597A (ja) ムスカリン性アセチルコリンｍ１受容体アンタゴニストの結晶性化合物
CN115397466A (zh) 新型3，5-二氨基苯甲酸系化合物和使用该化合物的Pin1抑制剂以及炎症性疾病的治疗剂
TW200539857A (en) Methods for treating multiple sclerosis and pharmaceutical compositions therefor
RU2776845C2 (ru) Аналоги целастрола
US20130317034A1 (en) Combination therapy for treating diabetes
US20240226069A1 (en) Vafidemstat for use in treating autism spectrum disorders
JP2019142815A (ja) 心不全改善剤
BR122023014342B1 (pt) Compostos análogos de celastrol, composição farmacêutica compreendendo ditos compostos e usos dos mesmos para tratar obesidade ou uma doença ou distúrbio relacionado à obesidade
WO2025057845A1 (ja) 抗老化剤、抗老化用経口組成物及び化合物の使用
JP3361100B2 (ja) Ｃｃｋ受容体アンタゴニストとしてのインドール誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220120

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220301

R150 Certificate of patent or registration of utility model

Ref document number: 7034078

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250